Kardigan, Inc. (KARD)
| Market Cap | 1.30B |
| Revenue (ttm) | n/a |
| Net Income | -288.78M |
| EPS | -17.13 |
| Shares Out | 93.50M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 675,773 |
| Open | 15.65 |
| Previous Close | 15.56 |
| Day's Range | 13.74 - 15.79 |
| 52-Week Range | 12.23 - 27.00 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 41.00 (+195.82%) |
| Est. Earnings | Nov 22, 2026 |
About KARD
Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases. The company develops and provides a portfolio of medicines that target the underlying pathophysiology of cardiovascular diseases, including primary and secondary cardiomyopathies leading to heart failure. It utilizes a proprietary research and development platform that integrates AI-based tools, real-world clinical data, and cardiac-specific analytics to optimize clinical study design, patient screening, and efficacy tracking. The... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for KARD stock is "Strong Buy." The 12-month stock price target is $41.0, which is an increase of 195.82% from the latest price.
News
Kardigan initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of Kardigan (KARD) with a Buy rating and $42 price target The company has defined large cardiovascular markets with first-to-market potential and three late stage st...
Kardigan initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Kardigan (KARD) with an Overweight rating and $50 price target Kardigan is a clinical-stage biotech targeting genetic dilated cardiomyopathy, calcific aortic va...
Kardigan initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Kardigan (KARD) with an Overweight rating and $50 price target
Kardigan initiated with an Outperform at Baird
Baird initiated coverage of Kardigan (KARD) with an Outperform rating and $43 price target The firm likes the company’s three asset precision cardiology portfolio. Danicamtiv has the potential to impr...
Kardigan initiated with an Outperform at William Blair
William Blair initiated coverage of Kardigan (KARD) with an Outperform rating. Kardigan is a clinical-stage cardiovascular company that applies precision medicine and AI-enabled cardiac data to develo...
Kardigan initiated with a Buy at UBS
UBS analyst Alice Nettleton initiated coverage of Kardigan (KARD) with a Buy rating and $25 price target The company is building a precision cardiology franchise that currently includes three Phase…
Kardigan appoints Kristin Reinke to board of directors
Kardigan (KARD) announced the appointment of Kristin Reinke to its Board of Directors, where she will serve as chair of the Audit Committee. As part of the Board’s public company…
Kardigan Announces Appointment of Kristin Reinke to its Board of Directors
SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #Kardigan--Kardigan announced today the appointment of Kristin Reinke to its Board of Directors, where she will serve as chair ...
Kardigan Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
A platform-focused cardiovascular innovator highlighted its late-stage pipeline in genetic cardiomyopathy and aortic stenosis, leveraging adaptive trial designs and real-world data integration. Key programs danicamtiv and ataciguat are advancing through pivotal trials, with major data readouts expected next year.
Kardigan to Present at Two September Investor Conferences
SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #Kardigan--Kardigan will participate in two upcoming investor conferences: 2026 Cantor Global Healthcare Conference and Baird's...
Kardigan Slides: Corporate presentation
Kardigan has posted slides in relation to its latest quarterly earnings report, which was published on September 1, 2026.
Kardigan price target lowered to $46 from $51 at JPMorgan
JPMorgan lowered the firm’s price target on Kardigan (KARD) to $46 from $51 and keeps an Overweight rating on the shares. The firm updated models in the smid-cap biotech space.
Kardigan reports Q2 EPS ($4.61) vs ($4.64) last year
Cash, cash equivalents and investments were $660.7M as of June 30, 2026, compared to $335.5M as of December 31, 2025. “Our IPO has positioned Kardigan (KARD) to advance a portfolio…
Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates
SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #CVD--Kardigan™, Inc. (Nasdaq: KARD) today reported financial results from the second quarter ended June 30, 2026, and provided...
Kardigan Earnings release: Q2 2026
Kardigan released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Kardigan Quarterly report: Q2 2026
Kardigan has published its Q2 2026 quarterly earnings report on August 11, 2026.
Kardigan initiated with an Outperform at Leerink
Leerink initiated coverage of Kardigan (KARD) with an Outperform rating and $37 price target
Kardigan initiated with a Buy at TD Cowen
TD Cowen analyst Ritu Baral initiated coverage of Kardigan (KARD) with a Buy rating and $46 price target The company’s late-stage precision cardiology assets target the root causes of cardiovascular…
Kardigan initiated with an Overweight at JPMorgan
JPMorgan initiated coverage of Kardigan (KARD) with an Overweight rating and $51 price target The firm sees each of Kardigan’s mid-stage cardiovascular pipeline assets as having “early de-risking proo...
Kardigan initiated with a Buy at Jefferies
Jefferies initiated coverage of Kardigan (KARD) with a Buy rating and $40 price target The firm sees “value creating catalysts” for the company’s three specialty cardiology programs in the first…
Kardigan Slides: Investor presentation
Kardigan has posted slides in relation to its latest quarterly earnings report, which was published on July 1, 2026.
Kardigan Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #Kardigan--Kardigan announced the closing of its initial public offering.
Kardigan rises in Nasdaq debut after upsized $400 million IPO
Kardigan's shares rose 1.6% in their Nasdaq debut on Thursday, after the heart drug developer raised $400 million in an upsized U.S. initial public offering.
Kardigan Announces Pricing of Upsized Initial Public Offering
SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #Kardigan--Kardigan™, Inc. (Nasdaq: KARD) (“Kardigan”), a clinical-stage precision therapeutics company developing medicines th...
Heart drug developer Kardigan targets $1.4 billion valuation in US IPO
Kardigan is targeting a valuation of up to $1.4 billion in its initial public offering in the United States, the drug developer said on Thursday.